LT2776065T - Kombinuotos terapijos, panaudojančios prieš pseudomonas psl ir pcrv nukreiptas, juos surišančias molekules - Google Patents
Kombinuotos terapijos, panaudojančios prieš pseudomonas psl ir pcrv nukreiptas, juos surišančias molekulesInfo
- Publication number
- LT2776065T LT2776065T LTEP12847479.8T LT12847479T LT2776065T LT 2776065 T LT2776065 T LT 2776065T LT 12847479 T LT12847479 T LT 12847479T LT 2776065 T LT2776065 T LT 2776065T
- Authority
- LT
- Lithuania
- Prior art keywords
- binding molecules
- combination therapies
- pseudomonas psl
- pcrv binding
- pcrv
- Prior art date
Links
- 241000589516 Pseudomonas Species 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161556645P | 2011-11-07 | 2011-11-07 | |
US201261625299P | 2012-04-17 | 2012-04-17 | |
US201261697585P | 2012-09-06 | 2012-09-06 | |
PCT/US2012/063722 WO2013070615A1 (en) | 2011-11-07 | 2012-11-06 | Combination therapies using anti- pseudomonas psl and pcrv binding molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
LT2776065T true LT2776065T (lt) | 2020-10-12 |
Family
ID=48290482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP12847479.8T LT2776065T (lt) | 2011-11-07 | 2012-11-06 | Kombinuotos terapijos, panaudojančios prieš pseudomonas psl ir pcrv nukreiptas, juos surišančias molekules |
Country Status (22)
Country | Link |
---|---|
US (3) | US10597439B2 (lt) |
EP (1) | EP2776065B1 (lt) |
JP (1) | JP6182152B2 (lt) |
KR (1) | KR102184343B1 (lt) |
CN (1) | CN104136042B (lt) |
AU (3) | AU2012336028A1 (lt) |
BR (1) | BR112014011028B1 (lt) |
CA (2) | CA2854817C (lt) |
CY (1) | CY1123552T1 (lt) |
DK (1) | DK2776065T3 (lt) |
ES (1) | ES2859323T3 (lt) |
HK (1) | HK1201453A1 (lt) |
HR (1) | HRP20201370T1 (lt) |
HU (1) | HUE050985T2 (lt) |
LT (1) | LT2776065T (lt) |
MX (1) | MX2014005566A (lt) |
PL (1) | PL2776065T3 (lt) |
PT (1) | PT2776065T (lt) |
RS (1) | RS60920B1 (lt) |
RU (1) | RU2687588C2 (lt) |
SI (1) | SI2776065T1 (lt) |
WO (1) | WO2013070615A1 (lt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012170807A2 (en) | 2011-06-10 | 2012-12-13 | Medimmune, Llc | Anti-pseudomonas psl binding molecules and uses thereof |
SI2776065T1 (sl) | 2011-11-07 | 2020-10-30 | Medimmune Limited | Kombinacijske terapije z uporabo molekul, ki vežejo anti-Pseudomonas Psl in PcrV |
CA2863468A1 (en) * | 2012-03-02 | 2013-09-06 | Ablynx Nv | Pseudomonas aeruginosa pcrv binding single variable domain antibodies |
JP2015535005A (ja) * | 2012-11-06 | 2015-12-07 | メディミューン,エルエルシー | 抗シュードモナス属(Pseudomonas)PslおよびPcrV結合分子を用いた併用治療 |
WO2014186358A2 (en) * | 2013-05-14 | 2014-11-20 | Antonio Digiandomenico | Synthetic oligosaccharide subunits of the psl exoplysaccharide of pseudomonas aeruginosa and uses therof |
EP3139950A4 (en) * | 2014-05-05 | 2017-12-20 | Medimmune, LLC | Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof |
TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
WO2016179101A2 (en) * | 2015-05-01 | 2016-11-10 | Inhibrx Lp | Type iii secretion system targeting molecules |
RU2018107056A (ru) * | 2015-08-24 | 2019-09-26 | МЕДИММЬЮН, ЭлЭлСи | Полипептиды mrka, антитела к ним и пути их применения |
JP7110095B2 (ja) * | 2015-11-30 | 2022-08-01 | メドイミューン・リミテッド | 院内肺炎を予防または治療する方法 |
US20190153076A1 (en) * | 2016-05-05 | 2019-05-23 | The Trustees Of The University Of Pennsylvania | DNA Antibody Constructs for Use against Pseudomonas Aeuruginosa |
MA54975B1 (fr) | 2019-06-11 | 2023-08-31 | Regeneron Pharma | Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation |
JP7478807B2 (ja) * | 2019-07-09 | 2024-05-07 | 北京三▲諾▼佳邑生物技▲術▼有限▲責▼任公司 | シュードモナス菌PcrVを特異的に認識する抗体及びその使用 |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
CN114072145B (zh) * | 2020-06-01 | 2024-06-11 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别假单胞菌pcrv的抗体及其用途 |
KR20230065262A (ko) * | 2020-08-07 | 2023-05-11 | 베이징 솔로바이오 진테크놀로지 컴퍼니 리미티드 | 슈도모나스 psl을 특이적으로 인식하는 항체 및 이의 용도 |
FR3114970B1 (fr) | 2020-10-08 | 2023-06-30 | Univ Tours | Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires |
US20240002482A1 (en) * | 2020-11-18 | 2024-01-04 | Beijing Solobio Genetechnology Co., Ltd. | Combinations of Antibodies and Bispecific Antibodies Comprising Antigen-Binding Specifically Recognizing Pseudomonas PcrV and Psl |
WO2023141611A2 (en) * | 2022-01-21 | 2023-07-27 | Lyvgen Biopharma Holdings Limited | Multi-specific antibodies in uses thereof in avidity receptor crosslinking and immune modulation |
WO2024003103A1 (en) | 2022-06-29 | 2024-01-04 | Astrazeneca Ab | Anti-pcrv and psl bispecific antibodies for treatment of bronchiectasis |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
EP0215131B1 (en) | 1985-03-11 | 1992-06-17 | Teijin Limited | E87ag antigen of pseudomonas aeruginosa, monoclonal antibody against it, and hybridoma |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
US6420140B1 (en) | 1996-10-11 | 2002-07-16 | Abgenix, Inc. | Production of multimeric protein by cell fusion method |
US6190370B1 (en) | 1997-07-25 | 2001-02-20 | Arrow International, Inc. | Devices, systems and methods for determining proper placement of epidural catheters |
EP1348715A3 (en) | 1998-04-21 | 2003-11-19 | Micromet AG | CD19xCD3 specific polypeptides and uses thereof |
ES2255329T3 (es) | 1998-11-25 | 2006-06-16 | Mcw Research Foundation, Inc. | Metodo y composiciones para inmunizacion con el antigeno v de pseudomonas aeruginosa. |
US7858559B2 (en) | 2000-11-17 | 2010-12-28 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
ES2275840T3 (es) * | 2001-01-26 | 2007-06-16 | Mcw Research Foundation, Inc. | Metodo y composiciones para inmunizar con el antigeno v de pseudomonas. |
AU2002327164A1 (en) | 2001-01-29 | 2002-12-09 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
US20020146753A1 (en) | 2001-04-06 | 2002-10-10 | Henrik Ditzel | Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease |
US7119172B2 (en) | 2001-05-21 | 2006-10-10 | The Brigham And Women's Hospital, Inc. | P. aeruginosa mucoid exopolysaccharide specific binding peptides |
US20030232387A1 (en) | 2002-06-14 | 2003-12-18 | Millennium Pharmaceuticals, Inc. | Antibodies that bind alphaE integrin |
CA2618482C (en) | 2005-08-19 | 2014-10-07 | Abbott Laboratories | Dual variable domain immunoglobin and uses thereof |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US20090215992A1 (en) | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
CA2655372A1 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
JP2008133206A (ja) * | 2006-11-28 | 2008-06-12 | Yokohama City Univ | 緑膿菌に対して感染防御能を誘導できる医薬組成物 |
US7553936B2 (en) * | 2006-12-04 | 2009-06-30 | The United States of America as represented by Secretary Department of Health and Human Services | Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions |
WO2008074840A2 (en) | 2006-12-19 | 2008-06-26 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders |
NZ586357A (en) | 2007-11-30 | 2012-10-26 | Kalobios Pharmaceuticals Inc | Antibodies to the pcrv antigen of pseudomonas aeruginosa |
EP2599792A1 (en) | 2008-01-10 | 2013-06-05 | Shionogi&Co., Ltd. | Antibody directed against PcrV |
AU2009205995B2 (en) | 2008-01-18 | 2014-04-03 | Medimmune, Llc | Cysteine engineered antibodies for site-specific conjugation |
RU2011126338A (ru) | 2008-11-28 | 2013-01-10 | Эбботт Лэборетриз | Стабильные композиции антител и способы их стабилизации |
JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
CN102264608B (zh) * | 2008-12-31 | 2013-10-23 | W.L.戈尔有限公司 | 通风装置 |
JP2012516897A (ja) * | 2009-02-04 | 2012-07-26 | カロバイオス ファーマシューティカルズ インコーポレイティッド | シュードモナス・エルギノーサ(PseudomonasAeruginosa)感染の治療のための抗生物質と抗体療法との組み合わせ |
BRPI1008977A2 (pt) * | 2009-03-11 | 2016-10-04 | Shionogi & Co | anticorpo para pcrv humanizado que possui atividade anti-pseudomonal |
EP2408475B1 (en) * | 2009-03-18 | 2017-11-15 | Wake Forest University Health Sciences | Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa |
WO2010108153A2 (en) | 2009-03-20 | 2010-09-23 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
JP2012523221A (ja) | 2009-04-09 | 2012-10-04 | ケンタ バイオテク アーゲー | 緑膿菌(Pseudomonasaeruginosa)のIATSO1血清型のリポ多糖類(LPS)に対して特異的なヒトモノクローナル抗体 |
BRPI1015234A2 (pt) | 2009-06-22 | 2018-02-20 | Medimmune Llc | regiões fc projetadas para conjugação sítio específica. |
US8642039B2 (en) | 2009-12-22 | 2014-02-04 | Kalobios Pharmaceuticals, Inc. | Method of treating a staphylococcus infection in a patient having a low-level pathogenic Pseudomonas aeruginosa infection |
CA2826566C (en) * | 2011-02-08 | 2022-09-13 | Medimmune, Llc | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
WO2012145626A1 (en) | 2011-04-22 | 2012-10-26 | Ancora Pharmaceuticals Inc. | Synthetic oligosaccharides for staphylococcus vaccine |
WO2012170807A2 (en) | 2011-06-10 | 2012-12-13 | Medimmune, Llc | Anti-pseudomonas psl binding molecules and uses thereof |
US9580509B2 (en) * | 2011-11-07 | 2017-02-28 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
SI2776065T1 (sl) | 2011-11-07 | 2020-10-30 | Medimmune Limited | Kombinacijske terapije z uporabo molekul, ki vežejo anti-Pseudomonas Psl in PcrV |
CA2863468A1 (en) * | 2012-03-02 | 2013-09-06 | Ablynx Nv | Pseudomonas aeruginosa pcrv binding single variable domain antibodies |
JP2015535005A (ja) * | 2012-11-06 | 2015-12-07 | メディミューン,エルエルシー | 抗シュードモナス属(Pseudomonas)PslおよびPcrV結合分子を用いた併用治療 |
SG11201503231YA (en) | 2012-11-06 | 2015-05-28 | Medimmune Llc | METHODS OF TREATING <i>S. AUREUS</i>-ASSOCIATED DISEASES |
SG11201503232TA (en) * | 2012-11-06 | 2015-05-28 | Medimmune Llc | Antibodies to s. aureus surface determinants |
WO2014186358A2 (en) | 2013-05-14 | 2014-11-20 | Antonio Digiandomenico | Synthetic oligosaccharide subunits of the psl exoplysaccharide of pseudomonas aeruginosa and uses therof |
EP3139950A4 (en) * | 2014-05-05 | 2017-12-20 | Medimmune, LLC | Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof |
TWI719938B (zh) * | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
JP7110095B2 (ja) * | 2015-11-30 | 2022-08-01 | メドイミューン・リミテッド | 院内肺炎を予防または治療する方法 |
US20190153076A1 (en) * | 2016-05-05 | 2019-05-23 | The Trustees Of The University Of Pennsylvania | DNA Antibody Constructs for Use against Pseudomonas Aeuruginosa |
MA54975B1 (fr) * | 2019-06-11 | 2023-08-31 | Regeneron Pharma | Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation |
-
2012
- 2012-11-06 SI SI201231834T patent/SI2776065T1/sl unknown
- 2012-11-06 ES ES12847479T patent/ES2859323T3/es active Active
- 2012-11-06 MX MX2014005566A patent/MX2014005566A/es active IP Right Grant
- 2012-11-06 DK DK12847479.8T patent/DK2776065T3/da active
- 2012-11-06 RU RU2014122990A patent/RU2687588C2/ru active
- 2012-11-06 CN CN201280054651.8A patent/CN104136042B/zh active Active
- 2012-11-06 HU HUE12847479A patent/HUE050985T2/hu unknown
- 2012-11-06 EP EP12847479.8A patent/EP2776065B1/en active Active
- 2012-11-06 US US14/356,500 patent/US10597439B2/en active Active
- 2012-11-06 AU AU2012336028A patent/AU2012336028A1/en not_active Abandoned
- 2012-11-06 PT PT128474798T patent/PT2776065T/pt unknown
- 2012-11-06 BR BR112014011028-0A patent/BR112014011028B1/pt active IP Right Grant
- 2012-11-06 PL PL12847479T patent/PL2776065T3/pl unknown
- 2012-11-06 WO PCT/US2012/063722 patent/WO2013070615A1/en active Application Filing
- 2012-11-06 LT LTEP12847479.8T patent/LT2776065T/lt unknown
- 2012-11-06 JP JP2014540196A patent/JP6182152B2/ja active Active
- 2012-11-06 CA CA2854817A patent/CA2854817C/en active Active
- 2012-11-06 RS RS20201211A patent/RS60920B1/sr unknown
- 2012-11-06 CA CA3161431A patent/CA3161431A1/en active Pending
- 2012-11-06 KR KR1020147015274A patent/KR102184343B1/ko active IP Right Grant
-
2015
- 2015-02-27 HK HK15101962.5A patent/HK1201453A1/xx unknown
-
2017
- 2017-08-25 AU AU2017219081A patent/AU2017219081B9/en active Active
-
2019
- 2019-09-05 AU AU2019226205A patent/AU2019226205A1/en not_active Abandoned
-
2020
- 2020-02-13 US US16/789,790 patent/US11203633B2/en active Active
- 2020-08-28 HR HRP20201370TT patent/HRP20201370T1/hr unknown
- 2020-10-08 CY CY20201100949T patent/CY1123552T1/el unknown
-
2021
- 2021-11-15 US US17/454,837 patent/US20220177554A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1201453A1 (en) | Combination therapies using anti- pseudomonas psl and pcrv binding molecules psl pcrv | |
HUS2100034I1 (hu) | ANGPTL3-ellenes antitestek és alkalmazásaik | |
IL281250A (en) | Anti-PHF-tau antibodies and uses thereof | |
IL288203B (en) | Meditops and Meditop binding antibodies and their use | |
HK1257190A1 (zh) | 抗假單胞菌psl結合分子及其用途 | |
IL232399A0 (en) | Anti-2fgfr antibodies and their use | |
EP2756094A4 (en) | ANTI-B7-H4 ANTIBODIES AND USES THEREOF | |
SG11201502937PA (en) | COMBINATION THERAPIES USING ANTI-<i>PSEUDOMONAS</i> PSL AND PCRV BINDING MOLECULES |